Rituximab, a genetically engineered chimeric monoclonal antibody specifically binding to CD20, was the first antibody approved by the U.S. Food and Drug Administration for the treatment of cancer. Rituximab significantly improves treatment outcome in relapsed or refractory, low-grade or follicular B-cell nonHodgkin's lymphoma (NHL). However, there are also some challenges for us to overcome: why ϳ50% of patients are unresponsive to rituximab in spite of the expression of CD20, and why some responsive patients develop resistance to further treatment. Although the antitumor mechanisms of rituximab are not completely understood, several distinct antitumor activities of rituximab have been suspected, including complementdependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), apoptosis, and direct growth arrest. To counteract resistance to rituximab therapy, several strategies have been developed to: (a) augment the CDC effect by increasing CD20 expression, heteroconjugating rituximab to cobra venom factor and C3b, and inhibiting membrane complement regulatory protein, especially CD59, function; (b) enhance the ADCC effect through some immunomodulatory cytokines and CR3-binding ␤-glucan; and (c) reduce the apoptotic threshold or induce apoptotic signaling on the tumor. Extensive studies indicate that rituximab combined with these approaches is more effective than a single rituximab approach. Herein, the mechanism of action of and resistance to rituximab therapy in B-cell NHL, in particular, the involvement of the complement system, are extensively reviewed. The Oncologist 2008;13: 954 -966 
INTRODUCTION
Non-Hodgkin's lymphoma (NHL) is a diverse group of lymphatic malignancies distinct from Hodgkin's lymphoma on the basis of their epidemiology, clinical manifestation, therapy, and prognosis, as well as laboratory tests, including pathological features. The incidence of NHL has been steadily rising, currently ranking fifth in cancer mortality in the U.S. The annual incidence of NHL in 2000 -2004 was 19.3 cases per 100,000 persons, and approximately 66,120 new cases of NHL were expected to be diagnosed in 2008, representing 5% and 4% of all cancers in males and females, respectively [1] . NHL is classified as either B-cell or T-cell NHL. B-cell NHL is much more common than T-cell NHL. We focus on reviewing the current treatment of B-cell NHL, but not T-cell NHL.
In the past 10 years or more, significant progress has been made in specifically treating B-cell NHL. While traditional nonspecific cancer therapies such as chemotherapy and radiotherapy mainly focus on killing rapidly dividing cancer cells, they also kill rapidly dividing normal cells, thereby causing obvious multiple side effects. In contrast, specific targeted therapies, including immunotherapy, mainly kill cancer cells, with no or minimal effects on normal cells. Therefore, specific targeted therapies have obvious advantages and are increasingly becoming the preferred tools to conquer cancer. Immunotherapy that targets receptors using monoclonal antibodies (mAbs) has an established role in the treatment of certain leukemias, lymphomas, and breast cancers by specifically recognizing cancer cells [2] . Not only can mAbs conjugate with cytotoxic compounds, radionuclides, and toxins, but unconjugated mAbs can exert antitumor activity alone. To date, five mAbs, including three unconjugated mAbs, have been approved for cancer therapy by the U.S. Food and Drug Administration (FDA). Among the three unconjugated mAbs, the chimeric antibody rituximab, the first mAb approved by the FDA, has been successfully used in the treatment of Bcell NHL via targeting the membrane molecule of CD20 on B-cell lymphoma, with a great improvement in outcome [3] , and is also regarded as the driving force in our current focus on immunotherapy of B-cell NHL. Herein, the mechanism of action of and resistance to rituximab therapy in Bcell NHL, in particular, the involvement of the complement system, are described.
RITUXIMAB TARGETING CD20
Rituximab (IDEC-C2B8, Rituxan; IDEC Pharmaceuticals, San Diego, CA, and Genentech, Inc, San Francisco, CA) is a genetically engineered chimeric mAb that specifically binds to CD20, which contains human ␥-1 and constant regions with murine variable regions [4] . Rituximab therapy alone or in combination with chemotherapy has remarkably improved the treatment outcome of patients with B-cell NHL. Its single-agent efficacy with low toxicity was proven by an overall response rate of 50% with a median time to progression in responders of 13.2 months, but some responsive patients develop resistance to further rituximab treatment [5, 6] . The mechanism of rituximab unresponsiveness remains unclear, and rituximab resistance requires more extensive investigation.
The rituximab-targeted molecule, CD20, a 32-kDa nonglycosylated phosphoprotein, provides a universal target for immunotherapy, which is especially expressed on the surface of normal precursor and mature B cells and, importantly, not on early pre-B cells, stem cells, or antigenpresenting dendritic reticulum cells [7] . More than 90% of B-cell NHLs express this surface protein [8, 9] . The CD20 protein has four transmembrane domains and does not modulate from the cell surface in response to antibody binding, thus providing an excellent target for immunotherapeutic strategies [4] . So far, the natural ligand for CD20 has not been identified, and the biological function of CD20 remains unclear. CD20 knockout mice show normal B-cell development and function [10] . Via phage display libraries, Binder et al. [11] showed that rituximab binds a discontinuous conformational epitope on CD20, comprising (170)ANPS(173) and (182)YCYSI(185), with both strings brought in steric proximity by a disulfide bridge between C(167) and C(183). This structural interaction was further proven by crystal structure analysis of the complex of rituximab Fab fragment and CD20 fragment (aa163-aa187) [12] . Several distinct antitumor activities of rituximab have been suspected in B-cell NHL therapy, including complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), apoptosis, and direct growth arrest [13] . In addition, complement-dependent cellular cytotoxicity (CDCC) has often been included in ADCC [14] .
CDC The Complement System
The complement system, a central innate system, is the effector of adaptive immunity. It spontaneously identifies any potential pathogens and efficiently protects the host from intruding pathogen attack through a wide range of cellular responses [15] [16] [17] [18] . This system is composed of Ͼ30 soluble plasma proteins and membrane proteins that can trigger three distinct protease cascades known as the classical, mannose-binding lectin (MBL), and alternative pathways (Fig. 1) . The classical pathway is triggered by antigenbound antibody molecules and is initiated by the binding of a specific part of the antibody (Fc) to C1q [15] . The MBL pathway is initiated when plasma MBL in complex MBL and MBL-associated protease (MASP)-1/2 bind to arrays of carbohydrates (specifically mannose and fucose residues) on the surface of many pathogens such as bacteria, viruses, fungi, yeasts, and parasites; MASP-1/2 then cleaves C4 and triggers the subsequent complement cascade [16] . The alternative pathway is capable of spontaneous autoactivation, 955 Zhou, Hu, Qin termed the "tickover" of C3 at a rate of ϳ1% of total C3 per hour [19, 20] , thereby identifying any potential pathogens. All three pathways converge at the C3 level, which allows C3b to target the pathogens, and at the C5 level, which leads to polymerization of C9 by C5b-8 binding and to assembly of a membrane attack complex (MAC) with a diameter of 5-10 nm (Fig. 1) [15] . If the MAC inserted into the cell membrane remains open, it will directly induce targeted cell lysis through subsequent influx of ions and water that leads to lethal colloid-osmotic swelling, CDC. The CDC effect is characterized by swelling of mitochondria, dilation of the rough endoplasmic reticulum, disruption of the Golgi complex and of the plasma and nuclear membranes, and heterochromatin disappearance at the ultrastructural level involving the generation of reactive oxygen species [21, 22] . For targeted cell lysis, a single MAC is enough for erythrocytes but not for nucleated cells, because nucleated cells can endocytose MAC and repair the damage unless multiple MACs (12-to 16-mers) are assembled [23] .
The byproducts produced in complement activation, such as C1q, C3b, iC3b, and C4b, are critical opsonins for host defense against infection and for disposal of immune complexes and dead cell debris by the phagocytosis/lysis effect of the immune effector cells (macrophages, neutrophils, natural killer [NK] cells, etc.) through their surface receptor binding to these byproducts ( Fig. 1 and 2 ). On the other hand, the small fragment byproducts such as C3a, C4a, and C5a ( Fig. 1) , termed anaphylatoxins, also play an important role in inflammation and especially in host defense against parasites. These anaphylatoxins can cause mast cell and basophil degranulation, with the release of histamine and other substances that increase vascular permeability, stimulate smooth muscle constriction, and induce chemotaxis. The anaphylatoxins can also activate these immune effector cells by binding to cell surface receptors [24, 25] . Among these anaphylatoxins, C5a has the most potent biological activity.
To prevent the potentially harmful effect of complement activation on autologous cells, Ͼ10 plasma-and membrane-bound inhibitory proteins have evolved for restricting complement activation at different stages of activation pathways ( Fig. 1 and 2 ) [26, 27] . The soluble plasma complement regulatory proteins include C1 inhibitor, which regulates C1; factor H and factor I, which regulate the cleavage of C3b and C3/C5 convertases; C4 binding protein, which splits C4 convertase and assists factor I in the cleavage of C4b; and S-protein, clusterin, and serum lipids, which compete with membrane lipids for reacting with nascent C5b67 [15] . Membrane complement regulatory proteins (mCRPs) include: (a) CD46 (membrane cofactor protein), which regulates C3 activation by functioning as a cofactor protein for factor I-mediated cleavage of C3b and (membrane inhibitor of reactive lysis), which restricts MAC assembly on the cell membrane through binding to C8␣ and C9; (d) CD35 (complement receptor 1), which has both CD46 and CD55 functions in humans [26, 27, 30] and is a major immune adherence receptor that plays a role in immune-complex processing and clearance [31] ; and (e) complement-receptor 1-related protein y, present only in rats and mice, which possesses both CD46 and CD55 biological functions [32] [33] [34] [35] . CD55 and CD59 attach to the cell surface via a glycosylphosphatidylinositol (GPI) anchor, whereas CD46 and CD35 associate with the plasma membrane via their C-terminal transmembrane domains [36] . Structurally, CD55, CD46, and CD35 belong to the regulators of complement activation (RCA) family and contain a variable number of short consensus repeat domains. CD59 is a much smaller protein with no sequence or structural resemblance to the RCA family of proteins [27] . Several lines of evidence from human and animal studies indicate that CD59 is more relevant than CD55 and CD46 in protecting normal cells from MAC formation and MACinduced phenomena [37] [38] [39] [40] [41] [42] .
There is a delicate balance between complement activation and regulation on autologous cells that is subject to perturbation by either increased complement activation or decreased regulation, which may cause a variety of immune diseases. For example, immune-complex activation of the classical complement pathway results in autoimmune diseases such as systemic lupus erythematosus and glomerulonephritis [30, 43] . Conversely, deficiency of GPIanchored DAF and CD59 in circulating cells-resulting from an acquired somatic PIG-A gene mutation-is responsible for the hemolytic anemia and thrombosis that characterize paroxysmal nocturnal hemoglobinuria [44 -46] . However, the high expression level of mCRPs also confers protection on cancer cells, invading microorganisms including HIV for complement attack, and may lead to resistance to antibody therapy.
Rituximab-Mediated CDC
The formation of MACs and subsequent cytolysis are usually considered as the activity of CDC via activation of the classical pathway initiated by C1q binding to antibody Fc fragment in rituximab therapy (Fig. 2) . The consequence of the formation of MACs generally depends on the copy numbers assembled on the targeted tumor cells. Only at high copy numbers (12-to 16-mers) per cell (a lytic dose), can MACs induce a loss of membrane integrity and rapid necrotic-type cell death, possibly by a caspase-independent mechanism [21] [22] [23] 47] . At low copy numbers of MACs per cell (nonlytic or sublytic dose), MACs exhibit a wide range of effects leading to cellular responses such as secretion, adherence, aggregation, chemotaxis, and even cell proliferation activity through various cell-signaling pathways [48 -50] .
There is much evidence to highlight the importance of CDC in rituximab therapy of B-cell NHL. Complement depletion by cobra venom factor (CVF) significantly reduced the antitumor activity of rituximab in severe combined immunodeficiency (SCID), athymic nude mice [51, 52] . This activity was not affected by depletion of macrophages, NK cells, and/or neutrophils, which are irrelevant to CDC, in either a disseminated or s.c. tumor mouse model. It was also completely abolished in a C1q-deficient syngeneic mouse model and in a CVF complement-depleted mouse model Rituximab-mediated CDC effect and strategies for enhancing the CDC effect. C1q interacts with the rituximab Fc region exposed after binding to CD20 on the B-cell surface, thus activating the classical complement cascade, and a MAC is inserted into the cell membrane, with multiple MACs (12-to 16-mers) leading to cytolysis. Strategies to overcome resistance to the CDC effect include: (a) inhibitors of the mCRPs DAF and especially CD59, which leads to more complement activation and more MAC formation on the cell surface; (b) heteroconjugates of rituximab to CVF or C3b, and other Ag-Ab complexes targeting tumor cells, which enhance complement activation; and (c) other drugs that can upregulate the expression of CD20, which include the histone deacetylase inhibitor trichostatin A and protein kinase C activator bryostatin-1.
Abbreviations: Ag-Ab, antigen-antibody; CDC, complement-dependent cytotoxicity; CVF, cobra venom factor; DAF, decay-accelerating factor; MAC, membrane attack complex; MCP, membrane cofactor protein; mCRP, membrane complement regulatory protein. [53, 54] . Furthermore, use of inhibitors abrogating mCRP (such as CD55 and CD59) functions can facilitate rituximab therapy in B-cell NHL, confirming the importance of CDC. However, many groups have claimed that ADCC plays a pivotal role in the antiproliferative effect of rituximab. Bcell lymphomas were depleted in vivo mainly by innate monocytes/macrophages in an Fc␥R-dependent manner of isotype-specific mAb interactions with distinct Fc␥Rs. This rituximab-mediated ADCC effect on B-cell lymphomas is completely effective in C3-, C4-, or C1q-deficient mice [55] [56] [57] . The explanation for the discrepancy between rituximab-mediated CDC and ADCC is complex and far from convincing [3] . A number of factors, including tumor status, mCRP expression, tumor cell type, tumor-inoculating methods, and tumor growth period, may influence the contributions of CDC and ADCC differently. However, it is widely accepted that ADCC and CDC synergistically affect cytotoxicity in cancer cells through the ability of complement to promote inflammation and change the activation status of innate effectors [3] . The byproduct of anaphylatoxin C5a during CDC is pivotal in activating these effector cells and can upregulate the expression of activating Fc␥R and downregulate the expression of inhibitory Fc␥RIIb via interaction with the C5a receptor, which enhances the ADCC effect in tumors [58 -61] . Moreover, CDC-resistant cells are sensitive to ADCC and vice versa [62] .
The potency of CDC in rituximab therapy is partially correlated with the level of CD20 expression on the B-cell NHL cell membrane [22, 63] . The higher the CD20 level, the more MACs can be assembled. Subsequently, targeted cells are directly lysed. With B-cell NHL cells freshly isolated from patients, a level of CD20 expression of Ͼ50 ϫ 10 3 CD20 molecules per cell is a prerequisite for the lytic response arising from the mechanism of CDC [22] . A sigmoidal or linear correlation between the CD20 expression level and the rituximab-mediated killing effect further demonstrates the important role of CDC in the rituximab-mediated anticancer effect [22, 62, 63] . Other reports indicate that the efficacy of CDC in rituximab therapy may be determined by the expression levels of CD20 and mCRPs (CD55, and especially CD59) [64] , but not of individual CD20 or mCRPs [65, 66] .
Overcoming Resistance to Rituximab Through Enhancing the CDC Effect

Abrogating mCRP Function
The mCRPs CD46, CD55, and CD59 play a critical role in tumor resistance to rituximab-mediated CDC (Fig. 2) . These mCRPs are expressed widely in almost all cancer cells independent of their tissue of origin [13] . The various expression levels of mCRPs may be regulated by the selective stress of complement attack [67] , the stage of differentiation [68, 69] , and host factors of neighboring tumor or stromal cells. These mCRPs in tumor cells restrict complement activation cascades in distinct stages and reduce MAC formation, thereby profoundly protecting the tumor from rituximab-mediated CDC ( Fig. 1 and 2) . The rituximabresistant B-cell NHL cell lines of Raji and Ramos generated under the stress of rituximab and normal human serum (complement resource) exhibit upregulation of CD52 and the complement regulators CD55 and CD59, as well as downregulation of CD20 [67, 70] . The use of neutralizing antibodies abrogating the function of CD46, CD55, and CD59 markedly enhanced the antitumor activity of rituximab in vitro and in vivo [13, 14, 22, 63, 71, 72] . However, these antibodies are not applicable to clinical treatment because they would initiate undesired complement attack by binding to the host cells expressing mCRPs. To overcome this problem, Tedesco's group [73] developed two miniantibodies (MBs), MB-55 (against CD55) and MB-59 (against CD59), containing the human IgG 1 hinge-CH2-CH3 domains, two single-chain variable fragments (scFv) without Fc fragment, a region necessary for activating the classical pathway. Furthermore, they generated two heteroconjugates of bio-MB55 and bio-MB59 [74] through a three-step biotin-avidin system, which is currently employed in patients to target radionuclides to cancer cells for enhancing the anticancer effect [75] [76] [77] . They documented that these modified antibodies against CD55 and CD59 significantly increased the antitumor activity of rituximab in vitro [73] and in vivo [74] . Alternatively, enhanced susceptibility can be achieved by downregulating the expression of mCRPs. Knockdown of CD55 expression via siRNA transfection attenuated the resistance of B-cell lymphoma or breast cancer cells to complement-mediated cytolysis by treatment with rituximab or trastuzumab [78] . The chemotherapeutic drug fludarabine showed a synergistic effect with rituximab treatment in NHL tumors, likely through the downmodulation of the membrane expression of CD55 [78, 79] . Consistent with the critical role of CD59 for restricting MAC in normal cells, CD59 is also more relevant to protect tumor cells from immunotherapy including rituximab than CD46 and CD55. Therefore, it is imperative to develop effective and practicable inhibitors against mCRPs, especially CD59, for facilitating rituximab and even other antibodies in treating tumors. For this reason, we have searched for an inhibitor for human CD59. Intermedilysin (ILY), a cytolytic pore-forming toxin secreted by Streptococcus intermedius, lyses human cells exclusively because the toxin binds to human CD59 (hCD59) with high specificity [80 -82] . The specificity for hCD59 is derived from 958 binding of ILY domain 4 (ILYd4) to amino acids 42-58 in hCD59, which also participate in binding to C8 and C9 [81] . Thus, we hypothesize that truncated ILYd4 would abrogate hCD59 function and thereby increase antibody-mediated CDC in cancer cells. If this is the case, ILYd4 may represent an innovative adjuvant for cancer immunotherapy in general and for antibody-resistant cancers in particular.
Increasing CD20 Expression
It is of note that the level of CD20 expression is related to the number of MACs formed on rituximab-targeted lymphocytes via binding to CD20, which determines whether targeted tumor cells can be lysed by CDC or not. Thus, an increased level of CD20 expression might be a means to overcome resistance to CDC (Fig. 2) . However, rituximab-CD20 complex formed by rituximab binding to CD20 on the targeted cell membrane can be shaved by monocytes/ macrophages expressing Fc␥RI, a phenomenon called antigen modulation [83] [84] [85] (Fig. 2) . This shaving reaction starts within 1-40 hours after rituximab infusion, which could substantially compromise the therapeutic efficacy of rituximab [85] . Interestingly, the histone deacetylase inhibitor suberoylanilide hydroxamic acid modulated the expression of apoptosis-related genes [86] , and another histone, deacetylase inhibitor trichostatin A, could epigenetically increase CD20 mRNA and protein expression in an established CD20-negative cell line to sensitize rituximab therapy [87] . Bryostatin-1, a protein kinase C activator, can also enhance expression of CD20 at the level of both mRNA and protein in human tumor B cells through extracellular signal-related kinase (ERK)-dependent mechanisms, which in turn increases the susceptibility of the tumor to rituximab [88] . Moreover, synthetic CpG oligodeoxynucleotides are currently being tested in clinical trials as a vaccine adjuvant and for rituximab immunotherapy of B-cell NHL [89] . Synthetic CpG oligodeoxynucleotides resembling sequences found in bacterial DNA specifically increase primary malignant B-cell expression of CD20, thereby resulting in enhanced sensitivity to rituximab treatment [89, 90] .
Enhancing Complement Activation
Besides abrogating mCRP function and increasing the CD20 expression level, an alternative strategy that can be employed to overcome resistance to CDC is to directly enhance complement activation on tumor cells. A complement-activating protein such as CVF or C3b can be conjugated to the antitumor antibody for the enhancement of complement activation [91] (Fig. 2) . This effect was achieved in vitro by either anti-epithelial cell adhesion molecule-CVF heteroconjugates targeted to colorectal cancer cells [92] or anti-GD2-CVF heteroconjugates targeted to neuroblastoma cells [93, 94] . Additionally, an antibody against iC3b was demonstrated to increase iC3b deposition, which allowed it to interact with effector cells containing both Fc and complement receptors, and therefore significantly enhancing rituximab-mediated killing of Raji and DB cells in a cynomologous monkey model [95] (Fig. 2) .
ADCC
Effect of ADCC in Rituximab Therapy
Together with CDC, ADCC also plays an important role in rituximab antitumor activity. ADCC triggers tumor cell killing through interaction between the Fc region of CD20 binding rituximab and Fc␥Rs, particularly Fc␥RI and Fc␥RIII, activating receptors expressed on immune effector cells such as monocytes/macrophages, granulocytes/ neutrophils, and NK cells (Fig. 3) . This interaction, mediated by rituximab on activated effector cells, initiates a Figure 3 . Rituximab-mediated ADCC and strategies to enhance the ADCC effect. CDCC is also classified here, which normally has little efficacy in rituximab therapy. This kind of cellular cytotoxicity can occur after binding of either the rituximab Fc region (in ADCC) or C1q, C3b, C4b, and iC3b (in CDCC) to their respective receptors, resulting in either phagocytosis or cell-mediated lysis of B-lymphocytes, depending on the effector cell type. The Fc region of cell-bound rituximab is recognized principally by either the activating receptors Fc␥RI/Fc␥RIII or the inhibitory receptor Fc␥RIIB, whereas the byproducts of complement activation are recognized by C1qR, CR1, or CR3 on effector cell surfaces. The strategies to overcome resistance to the ADCC/CDCC effect include: (a) anaphylatoxins (C5a, C3a); (b) some cytokines (IL-2, IL-12, M-CSF) that are able to activate effector cells; and (c) CR3-specific polysaccharides such as ␤-glucan, which primes CR3 and therefore triggers cellular cytotoxicity.
Abbreviations: ADCC, antibody-dependent cellular cytotoxicity; CDCC, complement-dependent cellular cytotoxicity; CR, complement receptor; IL, interleukin. 959 Zhou, Hu, Qin series of signaling pathways that lead to the release of inflammatory and/or cytotoxic immune modulators including cytokines, chemokines, proteases, and reactive oxygen species. Eventually, the activated monocytes/macrophages and granulocytes/neutrophils phagocytose the targeted cancer cells, whereas activated NK cells eliminate targeted lymphoma cells using the granzyme-perforin system. Generally, the resting effector cells where the inhibitory Fc␥RIIB is dominantly expressed cannot function unless activated. The inhibitory Fc␥RIIB is a potent regulator of ADCC in vivo, modulating the activity of Fc␥RIII on effector cells [96] . The antitumor activity of rituximab is greatly reduced in Fc␥RI/Fc␥RIII-deficient mice, whereas disruption of the gene that encodes the inhibitory receptor Fc␥RIIB substantially enhanced antitumor activity. In addition, rituximab can induce the ␤-chemokine CCL3 in vivo, activating innate immune cells such as NK cells, macrophages, and polymorphonuclear cells, which increases the ADCC effect [52] . These results suggest that rituximab-mediated ADCC is important for killing cancer cells [96, 97] .
CDCC may also be engaged in destroying invading pathogens. In CDCC, deposition of C3b, iC3b, C1q, and C4b bound on the surface of targeted cells is able to opsonize phagocytosis through binding to their receptors on monocytes/macrophages, NK cells, and polymorphonuclear leukocytes [95, 98, 99] (Fig. 3) . This process can be further enhanced by chemotactic and cell-activating anaphylatoxins such as C5a and C3a through their receptors on the above phagocytes [24, 25] , which are pivotal mediators of the host defense against infection and of the disposal of immune complexes and products of inflammatory injury [16] . To date, there has been little research on the effect of CDCC on rituximab therapy, perhaps because of its relative ineffectiveness [14] .
Enhancing ADCC
Antibody-targeted tumor resistance to innate immune cells such as macrophages, NK cells, and neutrophils in ADCC may arise from the suppression of these immune effectors after long-term expansion of the tumor. Resistance to rituximab in some patients may be linked to a polymorphism in Fc␥RIIIa affecting isotype preference [100] . Genetically modified NK cells carrying a chimeric antigen receptor that consists of a CD20-specific scFv antibody fragment conferred enhanced cytotoxic activity and could overcome NK-cell resistance of lymphoma and leukemia cells [101] . In addition, the effect of some cytokines on ADCC-related resistance was tested. M-CSF in vitro enhanced the cytotoxicity of monocytes on Daudi B-cell lymphomas through upregulation of monocyte Fc␥RI and Fc␥RIII by 1.5-fold and 1.6-fold, respectively, whereas the expression of Fc␥RII remained unchanged [102] . Interleukin (IL)-2 is a pleiotropic cytokine that activates selective immune effector cell responses associated with antitumor activity, including ADCC. Golay et al. [103] demonstrated in vitro that IL-2-activated NK cells strongly enhanced the therapeutic activity of rituximab through ADCC in primary B-cell NHL cells freshly isolated from patients. Furthermore, IL-2 synergistically enhanced rituximab efficiency in killing B-cell NHL cells in a xenograft model, in part, through activation and trafficking of monocytes and NK cells to tumors [104] ; a similar result was obtained with an anti-CD20 -IL-2 immunocytokine [105] . Additionally, IL-12 synergizes the rituximab ADCC effect through upregulating ␥-interferon and interferon-inducible protein 10 expression and increasing NK cell lytic activity in vitro [106] (Fig. 3) . The concomitant use of IL-12 and rituximab had only a modest effect in treating patients with B-cell NHL. The response rate in patients treated with IL-12 in combination with rituximab did not seem to be better than that seen with rituximab alone. Also, the sequential administration of IL-12 after rituximab did not result in additional clinical responses [107] .
To enhance the CDCC effect in rituximab treatment, ␤-glucan can be applied to promote CR3-dependent cellular cytotoxicity. Generally, ␤-glucan is naturally exposed on the cell wall of yeasts and fungi. Moreover this CR3-mediated cytotoxicity that is responsible for host protection against yeast and fungus infection requires the binding of CR3 to both iC3b and ␤-glucan. Normally, this CDCC effect does not happen in rituximab therapy because tumor cells lack ␤-glucan [108] . However, together with deposited iC3b generated by rituximab-mediated complement activation, the administration of ␤-glucan can trigger cytotoxic phagocytosis and degranulation of iC3b-coated tumor cells [109, 110] , thus regressing tumor growth [110, 111] (Fig. 3) . The application of ␤-glucan has consistently been documented to markedly increase the therapeutic efficacy of rituximab in B-cell NHL-inoculated SCID mice [112] .
APOPTOSIS
Effect of Apoptosis in Rituximab Therapy
Deans et al. [113] [114] [115] [116] demonstrated that CD20 is associated with Src family tyrosine kinases, Lyn, Fyn, and Lck, which are involved in rituximab-induced apoptosis. CD20-associated PAG (phosphoprotein associated with GEMs [glycosphingolipid-enriched membrane microdomains]), also known as Csk-binding protein, is a ubiquitous, highly tyrosine-phosphorylated adaptor protein localized exclusively in lipid rafts [117, 118] . PAG normally recruits Csk 960 to lipid rafts to maintain resident Src family tyrosine kinases such as Lyn, Fyn, and Lck in an inactive state. After rituximab specifically binds to CD20, it redistributes lipid rafts, subsequently transactivates the above Src family tyrosine kinase, and initiates downstream signaling pathways resulting in apoptosis (Fig. 4) .
On the other hand, this redistribution of lipid rafts can also induce apoptosis by Fas molecule clustering. This clustering further induces the formation of the death-inducing signaling complex (DISC) and downstream activation of the death receptor (DR) pathway in Ramos B-cell NHL cells. Upon stimulation with rituximab and subsequent crosstalking with CD20, Fas-associated death domain protein (FADD) and caspase-8 were recruited into the DISC. This DISC was further confirmed by the identification of Fas, caspase-8, and FADD together with CD20 in sucrosegradient raft fractions [119] . Therefore, rituximab can sensitize lymphoma B cells to Fas-induced apoptosis in a caspase-8 -dependent manner (Fig. 4) .
Rituximab preferentially inhibits the expression of the antiapoptotic gene products Bcl-2/Bcl-xL, X-linked inhibitor of apoptosis protein, and myeloid cell leukemia sequence 1 in B-cell NHL cells through downregulating the p38 mitogen-activated protein kinase (MAPK), nuclear factor (NF)-B, ERK-1/2, and Akt survival pathways (Fig.  4) . The inhibition of these antiapoptosis-related pathways sensitizes B-cell NHL to undergo apoptosis and even to chemotherapy for killing drug-resistant B-cell NHL cell lines [6, 120 -122] . Furthermore, the inhibition of the NF-B pathway by rituximab treatment can subsequently block the downstream transcription repressor Yin Yang 1, thereby resulting in enhancement of the transcription of Fas-induced and DR5-induced apoptosis [123, 124] (Fig. 4) .
Rituximab also enhances apoptosis by an as yet unclear caspase-independent mechanism in B-cell NHL cells [125] [126] [127] [128] . A broad-spectrum caspase inhibitor, zVAD-fmk, prevented processing of caspase-9, caspase-3, and poly(ADPribose) polymerase (PARP) as well as DNA fragmentation, but did not block apoptosis as measured by annexin V staining, cell size, and membrane integrity in the rituximab response, which was also independent of Fas resistance and Bcl-2 overexpression. Rituximab-treated cells show leakage of adenylate kinase, surface expression of phosphatidylserine, upregulation of the cellular stress protein heat shock protein-70, phosphorylation of the survival protein Akt, and depolarization of the mitochondrial membrane but no loss of cytochrome c or apoptosis-inducing factor, which could not be blocked by caspase inhibitors. Furthermore, in cytoplasts that lack mitochondria and in Bcl-2-transfected cells, phosphatidylserine was still translocated to the cell surface after CD20 stimulation. Consistently, in support of these data, there is no cleavage of caspase-3, caspase-8, caspase-9, PARP, BH3-interacting domain death agonist, or genomic DNA. . Rituximab-induced apoptosis in therapy and strategies to enhance apoptosis. PAG normally recruits Csk to maintain the Src-family kinases Lyn, Fyn, and Lck in an inactivated state. CD20 -rituximab crosstalking can redistribute lipid rafts and thus transactivate these kinases and initiate downstream signaling pathways resulting in apoptosis. The redistribution of lipid rafts also induces apoptosis by Fas molecule clustering, which leads to the formation of DISC and the subsequent recruitment of FADD and caspase-8 into DISC, followed by the activation of the downstream apoptosis pathway. Meanwhile, the redistribution of lipid rafts can also inhibit the p38 MAPK, ERK-1/2, NF-B, and Akt signaling pathways and result in the inhibition of both transcription and expression of many genes, particularly the antiapoptotic genes Bcl-2, Bcl-xL, XIAP, and Mcl-1, thereby making B-lymphocytes susceptible to apoptosis. In addition, inhibition of the NF-B pathway downregulates the transcription factor YY1, enhancing the transcription of Fas and DR5 and facilitating FasL-and TRAIL-induced apoptosis. Evidence suggests a caspase-independent apoptosis pathway, whose mechanism needs more investigation. Strategies to enhance apoptosis after rituximab treatment include: (a) scFvRit:sFasL; (b) mapatumumab, a humanized monoclonal antibody targeting TRAIL receptor 1; (c) a recombinant protein, Apo2L/TRAIL, all three drugs target DRs to trigger the apoptosis pathway; and (d) other means such as antisense oligonucleotides of related apoptotic molecules and bortezomib, a proteasome inhibitor that induces apoptosis.
Abbreviations: DISC, death-inducing signaling complex; DR, death receptor; ERK, extracellular signal-related kinase; FADD, Fas-associated death domain protein; MAPK, mitogen-activated protein kinase; Mcl-1, myeloid cell leukemia sequence 1; NF-B, nuclear factor B; PAG, phosphoprotein associated with GEMs (glycosphingolipid-enriched membrane microdomains); TNF, tumor necrosis factor; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; XIAP, X-linked inhibitor of apoptosis protein; YY1, Yin Yang 1. 
Enhancing Apoptosis in Rituximab Therapy
Recently, the synergistic effect of apoptosis-inducing drugs in combination with rituximab in B-cell NHL treatment has received much attention and interest. A genetically engineered fusion protein, scFvRit:sFasL, containing a rituximab-derived antibody fragment and Fas ligand was successfully used in malignant B cells [129] (Fig. 4) . Mapatumumab, a humanized mAb that targets/activates tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) was able to augment the antitumor activity of rituximab via significant apoptosis [130] (Fig. 4) . Another recombinant human mAb, Apo2 ligand (Apo2L)/TRAIL, which was in clinical trials for selectively stimulating apoptosis in other cancer cells through its proapoptotic receptors DR4 and/or DR5, was strongly demonstrated to augment rituximab antitumor efficacy in mice inoculated with several different B-cell NHL cell lines [131] (Fig. 4) . Alternatively, the downregulation of the apoptosis-signaling molecule survivin or Bfl-1 expression by antisense oligonucleotides also sensitized rituximabmediated B-cell NHL cells to apoptosis [132, 133] (Fig.  4) . Research on patients suffering from relapsed or refractory cutaneous B-cell lymphoma disclosed a strong upregulation of the antiapoptotic molecule Bcl-2 compared with pretherapeutic levels, which suggests that upregulation of Bcl-2 plays a major role in therapy resistance [134] . Furthermore, Jazirehi et al. [135] generated rituximab-resistant B-cell NHL cell lines by increasing the concentration of rituximab in the culture medium, and then found lower expression of CD20 in these resistant clones. Interestingly, these clones exhibited hyperactivation of the p38 MAPK, NF-B, and ERK-1/2 pathways and overexpression of Bcl-2/Bcl-xL, indicating that the hyperactivation of these signaling pathways may be related to resistance. Therefore, it is reasonable to assume that the efficacy of rituximab will be enhanced in combination with antisense Bcl-2 oligonucleotides in SCID mouse/human lymphoma xenografts [136] . In addition, interference with hyperactivated signal pathways with various pharmacological and proteasome inhibitors reversed resistance (Fig. 4) . Bortezomib, a proteasome inhibitor, induced apoptosis earlier and sensitized resistant clones to various cytotoxic drugs and rituximab by preventing the degradation of proapoptotic factors and then activating caspase-8, caspase-9, caspase-3, and PARP [135, 137] . The development/acquisition of rituximab resistance may have arisen from perturbations of tumor cell survival signaling pathways and failure of rituximab to alter these pathways [6] .
DIRECT GROWTH ARREST
The binding of rituximab to CD20 can also induce direct growth arrest on lymphocytes. Bezombes et al. [138] demonstrated in vitro the direct inhibition of tumor growth by rituximab in Daudi and RL B-lymphoma cells. Rituximab induced moderate accumulation of tumor cells in the G 1 phase and significant loss of clonogenic potential without apoptosis. They observed that treatment with rituximab resulted in a rapid and transient increase in acid-sphingomyelinase activity and concomitant cellular ceramide generation in raft microdomains. This result suggests that rituximab-induced growth inhibition may be mediated through a ceramide-triggered signaling pathway, leading to the induction of cell cycle-dependent kinase inhibitors such as p27Kip1 through an MAPK-dependent mechanism. Therefore, rituximab mediates direct growth arrest, which may also contribute to its anticancer activity.
CONCLUSION
Although rituximab significantly improves the treatment outcome of B-cell NHL, it still has two challenges for us: unresponsiveness and resistance. Generally, the antitumor activity of rituximab is attributed to CDC, ADCC, apoptosis, and possible direct growth arrest, and CDC and ADCC are considered as the main effects. However, the contributions of CDC and ADCC are very controversial and require further investigation.
On the basis of the mechanisms described above, various strategies may be designed for triumphing over resistance to rituximab therapy. For example, complement activation in CDC can be enhanced by either increasing CD20 expression or heteroconjugating rituximab with CVF or C3b, or inhibiting mCRP (especially CD59) function. In particular, CD59 is a key inhibitor for MAC formation to escape the immunoresponse. Sublytic MAC is not sufficient to induce cytolysis, but may induce cell resistance by potentially increasing survival of cellsignaling pathways. Thus, it is imperative to develop an inhibitor of CD59 function. To enhance the ADCC effect, some immunomodulatory cytokines such as M-CSF, IL-2, and IL-12, as well as CR3-binding ␤-glucan, may offer effective strategies to increase the antitumor activity of rituximab. In addition, reduction of the apoptotic threshold or the induction of apoptotic signaling may also increase tumor susceptibility to rituximab treatment through Bcl-2 inhibitors and bortezomib as well as molecules targeting the tumor necrosis factor family receptor. In conclusion, although the rational combination of rituximab treatment with the above strategies toward clinical application requires further evaluation, this ap-962 proach has been extensively shown to be more effective than rituximab treatment alone.
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